Pertussis vaccine - ILiAD/INSERM

Drug Profile

Pertussis vaccine - ILiAD/INSERM

Alternative Names: BPZE 1

Latest Information Update: 07 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator INSERM; Institut Pasteur
  • Developer ILiAD Biotechnologies; INSERM; Institut Pasteur
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pertussis

Most Recent Events

  • 05 Jul 2017 Preclinical development in Pertussis is ongoing in France
  • 05 Jul 2017 ILiAD Biotechnologies has patent protection for BPZE1 technology
  • 05 Jul 2017 ILiAD Biotechnologies has patents pending for BPZE1 technology worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top